Join
Live feed
·
ANALYSTRatingvia Quantisnow
Kymera Therapeutics Inc. logo

Barclays resumed coverage on Kymera Therapeutics with a new price target

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KYMR (Kymera Therapeutics Inc.) and more on Quantisnow.